Revenue Growth Expectations:
The global bowel management systems market is projected to reach USD 2.07 billion by 2023 from USD 1.74 billion in 2018, at a CAGR of 3.5% during the forecast period.
Growth in the bowel management systems market is mainly driven by factors such as the expanding target patient and growing geriatric population, availability of technologically advanced bowel management products, and favorable reimbursement scenario in developed countries.
The colostomy bags segment is expected to form the largest segment during the forecast period.
Based on product, the bowel management systems market is categorized into four major segments, namely, irrigation systems, nerve modulation devices, colostomy bags, and other products & accessories. The colostomy bags segment is expected to account for the largest share in the bowel management systems market in 2018. Increasing number of target patient population, and growing availability of medical reimbursements for colostomy products across developed markets are expected to drive the growth of the colostomy bags segment in the next five years.
Download PDF Brochure@
Adult patients segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period
The bowel management systems market is segmented, by patient type, into adult and pediatric patients. The adult patients segment is expected to register the highest growth rate in the bowel management systems market during the forecast period, owing to the factors such as the significant prevalence of FI among adults, increased public-private initiatives to enhance patient awareness related to effective FI management, and availability of advanced bowel management products.
The home care segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period
The bowel management systems market is segmented, by end user, into home care and hospitals & ambulatory surgery centers. The home care segment is expected to register the highest growth rate of the bowel management systems market during the forecast period, owing to the factors such as the significant usage and growing adoption of bowel management products in home care settings, and need for device replacement on a regular basis.
In 2018, Europe accounted for the largest share of the bowel management systems market
Geographically, the bowel management systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe accounted for the largest share of the market in 2018. The large share can be attributed to the significant disease (colorectal/bladder cancer & IBD) burden, favorable reimbursement scenario, and the increase in its geriatric population.
Global Key Players:
Some of the major players operating in the bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (US), B. Braun (Germany), C.R. Bard (US), Consure Medical (India), Cogentix Medical (US), Aquaflush Medical Limited (UK), Axonics Modulation Technologies (US), ConvaTec (UK), Hollister (US), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (US), Welland Medical limited (UK), and Wellspect HealthCare (Sweden).
Request Sample Pages@
# In 2018, Coloplast acquired IncoCare, a provider of continence products. This acquisition helped Coloplast expand its presence in Germany.
# In 2018, Axonics received marketing approval for its Axonics Sacral Neuromodulation System in Australia.
# In 2018, Coloplast expanded its product portfolio by introducing a new product, SenSura Mio Concave, into its SenSura Mio product line.
# In 2016, ConvaTec entered into an agreement with Vizient, Inc. According to this agreement, members of Vizient get access to ConvaTec’s stoma care, bowel management, and patient skincare products.
# In 2016, A German court affirmed ConvaTec’s patent protection on Flexi-Seal Fecal Management System and ordered the competitor to cease from placing its product (infringing patent) in the market, as well as to recall its product already sent to market and to compensate ConvaTec.